Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL

Table 1

Clinical characteristic of men with positive and negative biopsy.

Median (IQR)	All patients		value
	Prostate cancer	Negative biopsy
No. pts	33	89
Age, mean (SD), years	68.4 (6.7)	64.1 (7.7)
PSA, mean (SD), ng/mL	7.0 (1.7)	7.2 (1.7)
Prostate volume, mL	51.6 (38.2, 69.7)	39.9 (28.0, 55.9)
% fPSA, %	15.0 (10.6, 18.5)	17.0 (13.3 to 22.7)
PCA3	125.0 (48.4, 252.7)	51.5 (14.5 to 104.7)
PSGR	160.3 (111.5, 298.9)	105.8 (32.9 to 187.0)
PSMA	62.7 (22.5, 120.9)	69.2 (25.4, 116.0)
MALTA-1	160.3 (101.4 to 499.5)	85.5 (31.1 to 151.8)
Positive DRE	11/33	20/89

IQR: interquartile range; no. pts: number of patients; PSA: prostate-specific antigen; % fPSA: percent free PSA; PCA3: prostate cancer antigen 3; PSGR: prostate-specific G protein coupled receptor; PSMA: prostate-specific membrane antigen; MALAT-1: metastasis-associated lung adenocarcinoma transcript 1; : Mann–Whitney test; : independent sample test; : chi-square test.